{{Rsnum
|rsid=12573606
|Gene=GRID1
|Chromosome=10
|position=87882302
|Orientation=plus
|GMAF=0.4421
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 36.3 | 46.0 | 17.7
| HCB | 48.2 | 45.3 | 6.6
| JPT | 63.7 | 33.6 | 2.7
| YRI | 2.7 | 29.9 | 67.3
| ASW | 5.3 | 47.4 | 47.4
| CHB | 48.2 | 45.3 | 6.6
| CHD | 55.0 | 35.8 | 9.2
| GIH | 35.6 | 45.5 | 18.8
| LWK | 3.6 | 25.5 | 70.9
| MEX | 39.7 | 44.8 | 15.5
| MKK | 11.0 | 45.2 | 43.9
| TSI | 43.1 | 47.1 | 9.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12573606
|Name_s=
|Gene_s=GRID1
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109410
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12573606
|overall_frequency_n=69
|overall_frequency_d=128
|overall_frequency=0.539062
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}